LONDON--(BUSINESS WIRE)--Market research firm Technavio has announced the release of their latest report on the global respiratory drugs market. This new report will provide expert market insights for the forecast period 2018-2022.
The report will follow up on Technavio’s previous respiratory drugs research, providing an up-to-date analysis of the market regarding the current market scenario, latest trends and drivers, and the overall global environment. The report will also provide new predictions for the forecast period based on an in-depth analysis of the market.
The upgraded research report on the global respiratory drugs market is an integral part of Technavio’s cardiovascular and metabolic disorders portfolio. Technavio covers an extensive range of market research reports on the cardiovascular and metabolic disorders market, focusing on the development of innovative compounds for novel targets. Some of the topics include biologic therapeutics, peptide therapeutics, liver cirrhosis therapeutics, and type 1 diabetes drugs.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Global opportunities for growth
Technavio’s previous report on the global respiratory drugs market projected that the Americas was the leading market for respiratory drugs in 2015 and will continue to dominate the market through 2020. The high incidence of respiratory diseases in regions such as the US, Canada, and Latin America is expected to promote the growth of the market in this region.
In the previous report, a senior research analyst at Technavio stated, “The increasing prevalence of respiratory diseases such as asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis will assist in the growth of this market during the forecast period. It was estimated that globally about 200 million people have asthma. This increase in the prevalence of respiratory disorders is expected to bolster the prospects for growth in the global respiratory drugs market over the years.”
Technavio’s new report on the global respiratory drugs market will evaluate the key geographical regions and their behavior over the past four years, introducing new data and observations and providing new predictions.
Looking for the latest information on the global respiratory drugs market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Detailed analysis at your fingertips
Some of the topics that will be revisited in the new report include:
- Market size and growth rate through 2022
- Key factors driving the market growth
- Competitive landscape and market share analysis of the key players
- Market opportunities and factors impeding growth
Technavio’s report on the global respiratory drugs market for the period 2018-2022 is available to order now and will be delivered within one week of purchase.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
